Business Context and Reporting Period
This Form 6-K is filed by Midatech Pharma PLC (noted as Biodexa Pharmaceuticals Plc in request metadata) for the month of July 2017. The filing serves solely to submit a previously announced License Agreement dated June 6, 2017, between Midatech Limited (a wholly owned subsidiary) and Novartis Pharma AG.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a contractual agreement and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the execution of a License Agreement with Novartis Pharma AG. Portions of the agreement have been omitted from this public filing as confidential treatment was requested and filed separately with the SEC.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the standard disclosure that confidential portions of the attached exhibit were omitted. The primary focus is the legal submission of the agreement.
Key Facts for Investor Verification
- The registrant is Midatech Pharma PLC, a foreign private issuer filing under Form 20-F.
- A License Agreement was executed on June 6, 2017, between Midatech Limited and Novartis Pharma AG.
- Specific financial terms and certain details of the agreement are confidential and were not included in this public filing.
- The filing was signed by Nicholas Robbins-Cherry, Chief Financial Officer, on July 19, 2017.